These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 1606628)
1. Molecular design of potent inhibitor specific for cathepsin B based on the tertiary structure prediction. Sumiya S; Yoneda T; Kitamura K; Murata M; Yokoo C; Tamai M; Yamamoto A; Inoue M; Ishida T Chem Pharm Bull (Tokyo); 1992 Feb; 40(2):299-303. PubMed ID: 1606628 [TBL] [Abstract][Full Text] [Related]
2. Structural basis for development of cathepsin B-specific noncovalent-type inhibitor: crystal structure of cathepsin B-E64c complex. Yamamoto A; Tomoo K; Matsugi K; Hara T; In Y; Murata M; Kitamura K; Ishida T Biochim Biophys Acta; 2002 Jun; 1597(2):244-51. PubMed ID: 12044902 [TBL] [Abstract][Full Text] [Related]
3. X-ray crystal structure of papain complexed with cathepsin B-specific covalent-type inhibitor: substrate specificity and inhibitory activity. Matsumoto K; Murata M; Sumiya S; Mizoue K; Kitamura K; Ishida T Biochim Biophys Acta; 1998 Mar; 1383(1):93-100. PubMed ID: 9546050 [TBL] [Abstract][Full Text] [Related]
4. Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. Murata M; Miyashita S; Yokoo C; Tamai M; Hanada K; Hatayama K; Towatari T; Nikawa T; Katunuma N FEBS Lett; 1991 Mar; 280(2):307-10. PubMed ID: 2013328 [TBL] [Abstract][Full Text] [Related]
5. pH Dependence of inhibitors targeting the occluding loop of cathepsin B. Cathers BE; Barrett C; Palmer JT; Rydzewski RM Bioorg Chem; 2002 Aug; 30(4):264-75. PubMed ID: 12392705 [TBL] [Abstract][Full Text] [Related]
6. Substrate specificity of bovine cathepsin B and its inhibition by CA074, based on crystal structure refinement of the complex. Yamamoto A; Tomoo K; Hara T; Murata M; Kitamura K; Ishida T J Biochem; 2000 Apr; 127(4):635-43. PubMed ID: 10739956 [TBL] [Abstract][Full Text] [Related]
7. Binding mode of CA074, a specific irreversible inhibitor, to bovine cathepsin B as determined by X-ray crystal analysis of the complex. Yamamoto A; Hara T; Tomoo K; Ishida T; Fujii T; Hata Y; Murata M; Kitamura K J Biochem; 1997 May; 121(5):974-7. PubMed ID: 9192742 [TBL] [Abstract][Full Text] [Related]
8. Effects of selective inhibition of cathepsin B and general inhibition of cysteine proteinases on lysosomal proteolysis in rat liver in vivo and in vitro. Ohshita T; Nikawa T; Towatari T; Katunuma N Eur J Biochem; 1992 Oct; 209(1):223-31. PubMed ID: 1382984 [TBL] [Abstract][Full Text] [Related]
9. Expression and alteration of the S2 subsite of the Leishmania major cathepsin B-like cysteine protease. Chan VJ; Selzer PM; McKerrow JH; Sakanari JA Biochem J; 1999 May; 340 ( Pt 1)(Pt 1):113-7. PubMed ID: 10229665 [TBL] [Abstract][Full Text] [Related]
10. Crystal structure of cathepsin B inhibited with CA030 at 2.0-A resolution: A basis for the design of specific epoxysuccinyl inhibitors. Turk D; Podobnik M; Popovic T; Katunuma N; Bode W; Huber R; Turk V Biochemistry; 1995 Apr; 34(14):4791-7. PubMed ID: 7718586 [TBL] [Abstract][Full Text] [Related]
11. The binding mode of an E-64 analog to the active site of cathepsin B. Feng MH; Chan SL; Xiang Y; Huber CP; Lim C Protein Eng; 1996 Nov; 9(11):977-86. PubMed ID: 8961350 [TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Structure-Activity Relationship Study of Epoxysuccinyl-Peptide Derivatives as Cathepsin B Inhibitors. Zhang X; Yang X; Wang H; Li S; Guo K; Jiang D; Xiao J; Liang D Biol Pharm Bull; 2017 Aug; 40(8):1240-1246. PubMed ID: 28502922 [TBL] [Abstract][Full Text] [Related]
13. Use of papain as a model for the structure-based design of cathepsin K inhibitors: crystal structures of two papain-inhibitor complexes demonstrate binding to S'-subsites. LaLonde JM; Zhao B; Smith WW; Janson CA; DesJarlais RL; Tomaszek TA; Carr TJ; Thompson SK; Oh HJ; Yamashita DS; Veber DF; Abdel-Meguid SS J Med Chem; 1998 Nov; 41(23):4567-76. PubMed ID: 9804696 [TBL] [Abstract][Full Text] [Related]
15. Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design. Greenspan PD; Clark KL; Tommasi RA; Cowen SD; McQuire LW; Farley DL; van Duzer JH; Goldberg RL; Zhou H; Du Z; Fitt JJ; Coppa DE; Fang Z; Macchia W; Zhu L; Capparelli MP; Goldstein R; Wigg AM; Doughty JR; Bohacek RS; Knap AK J Med Chem; 2001 Dec; 44(26):4524-34. PubMed ID: 11741472 [TBL] [Abstract][Full Text] [Related]
16. Crystallization and preliminary X-ray study of the cathepsin B complexed with CA074, a selective inhibitor. Yamamoto A; Kaji T; Tomoo K; Ishida T; Inoue M; Murata M; Kitamura K J Mol Biol; 1992 Oct; 227(3):942-4. PubMed ID: 1404397 [TBL] [Abstract][Full Text] [Related]
17. CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Buttle DJ; Murata M; Knight CG; Barrett AJ Arch Biochem Biophys; 1992 Dec; 299(2):377-80. PubMed ID: 1444478 [TBL] [Abstract][Full Text] [Related]
18. Development of cathepsin inhibitors and structure-based design of cathepsin B-specific inhibitor. Tomoo K Curr Top Med Chem; 2010; 10(7):696-707. PubMed ID: 20337581 [TBL] [Abstract][Full Text] [Related]
19. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. Musil D; Zucic D; Turk D; Engh RA; Mayr I; Huber R; Popovic T; Turk V; Towatari T; Katunuma N EMBO J; 1991 Sep; 10(9):2321-30. PubMed ID: 1868826 [TBL] [Abstract][Full Text] [Related]
20. Crystal structure of NS-134 in complex with bovine cathepsin B: a two-headed epoxysuccinyl inhibitor extends along the entire active-site cleft. Stern I; Schaschke N; Moroder L; Turk D Biochem J; 2004 Jul; 381(Pt 2):511-7. PubMed ID: 15084146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]